肿瘤细胞治疗研究
英文原题：CAR-T Therapies in Solid Tumors: Opportunities and Challenges.
CAR-T Therapies in Solid Tumors: Opportunities and Challenges.
由于恶劣的肿瘤微环境和肿瘤异质性，CAR-T 细胞治疗在血液系统恶性肿瘤中取得的类似成功尚未在实体瘤中观察到。
综述目的：本文讨论嵌合抗原受体（CAR）T细胞用于实体瘤时面临的挑战，以及克服这些障碍的机会；此外，还考察正在开发的儿童实体瘤疗法。近期发现：CAR-T细胞治疗血液系统恶性肿瘤取得的成功尚未在实体瘤中重现，原因包括肿瘤微环境恶劣和肿瘤异质性。为克服这些局限而开发的大多数策略强调联合治疗，但仍需进一步测试。包括GD2和HER2 CAR-T细胞在内的多项临床试验初步结果令人鼓舞，但仍须在更大规模研究中重复和验证。CAR-T细胞用于实体瘤仍具挑战性，目前大多数研究处于开发阶段。多项儿童实体瘤临床试验正在进行。早期结果显示出希望，但也表明需要改造CAR-T细胞以防止肿瘤复发。
PURPOSE OF REVIEW: This review will discuss the challenges facing chimeric antigen receptor (CAR)-T cell application for solid tumors and opportunities to overcome these obstacles. In addition, this review will examine therapies that are in development for pediatric solid tumors. RECENT FINDINGS: The similar success of CAR-T cell treatment for hematological malignancies has not been observed in solid tumors because of the hostile tumor microenvironment and tumor heterogeneity. Most strategies developed to combat these limitations emphasize combinatorial techniques that still require further testing. Preliminary results of multiple clinical trials, including GD2- and HER2-CAR-T cells, are encouraging but must be reproduced and validated on a larger scale. CAR-T cell application in solid tumors remains challenging, and most research is in development. Several clinical trials are ongoing for pediatric solid tumors. Early results are promising but demonstrate the need for CAR-T cell modification to prevent tumor recurrence.
MEMBER ACCOUNT
登录成功会直接打开下一页。
